Barcelona, October 25th, 2023: CPHI Barcelona announced the winners of the prestigious 2023 CPHI Pharma Awards. The awards recognise outstanding achievements and contributions from the global pharma industry and supply chain across 12 wide-ranging categories. InSyBio won the best Start-Up Initiative in Pharma for 2023.
CPHI is the biggest worldwide exhibition and event for the Pharma Industry and is organised annually. The CPHI Pharma Awards recognise progress and innovation across the pharma supply chain. The details about the CPHI awards and the awarded companies can be found at CPHI Awards.
In the CPHI awards 2023 press release (https://www.pharmiweb.com/press-release/2023-10-26/cphi-pharma-award-winners-2023), it is mentioned that: “InSyBio impressed the judges reviewing the brand-new Start-Up Initiative category for its ability to revolutionize the medical ﬁeld, clinical trials and food/nutrition industries through its targeted biomarker discovery. They have developed highly accurate predictive analytics enabling personalization of tests for drugs, nutraceuticals and nutrition products. Its solutions provide the R&D departments of Pharma, Research Institutes and Food/Nutrition companies with the means both analytically and computationally to meet their challenging research and innovation goals.”
Our CEO, Labros Digonis who received the award stated: “This award is a recognition of the hard work of our team in the past years to develop and commercialize a biomedical data analysis platform that could really expedite and speed up research in Pharma and Nutrition and eventually save lives. The CPHI event through the award as well as through our presence and exhibition in the start-up market, gave us the opportunity to connect with many pharma and nutraceutical product companies. We are looking forward to forming strong alliances that will lead to the development of personalized medicine and nutrition solutions”.
About InSyBio. InSyBio is an international pioneer biotechnology company revolutionizing the medical field through targeted biomarker discovery, highly accurate predictive analytics and the development of personalization tests for drugs. Its solutions provide the R&D departments of Pharma and Research Institutes with the means to meet their most challenging research and innovation goals. This is done through a sophisticated, software-as-a-service, machine learning platform which comprehensively integrates multi-omics and clinical data, thus reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals, and research centres allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and a decrease of at least 80% in overall time and cost. Visit http://www.insybio.com for more information.